ArticleObstetrics & gynecology science2026
Comparative prognostic performance of International Federation of Gynecology and Obstetrics 2023 staging system and the 2025 European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology-European Society of Pathology risk classification in endometrial cancer.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the prognostic performance of the International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system (FIGO 2023) and the 2025 European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology, and European Society of Pathology (ESGO 2025) risk classification in endometrial cancer (EC).
methodsWe retrospectively analyzed 296 patients who underwent primary surgical treatment for EC at a single tertiary institution. All cases were reclassified according to FIGO 2023 and ESGO 2025 using clinicopathological and molecular data. Recurrence-free survival (RFS) and disease-specific survival (DSS) were analyzed using the Kaplan-Meier method. Prognostic performance was assessed using the Akaike information criterion (AIC) and Harrell's concordance index (C-index) with bootstrap-derived 95% confidence intervals (CIs).
resultsKaplan-Meier analysis demonstrated significant differences in RFS and DSS according to both ESGO 2025 and FIGO 2023 (log-rank p<0.001). For recurrence prediction, ESGO 2025 showed better model fit than FIGO 2023, with a lower AIC value (410.849 vs. 428.644), and demonstrated a numerically higher C-index (0.8657; 95% CI, 0.8266-0.9114 vs. 0.8519; 95% CI, 0.8110-0.9005). In contrast, for disease-specific mortality prediction, FIGO 2023 showed better model fit than ESGO 2025, with a lower AIC value (143.758 vs. 148.109), and demonstrated a numerically higher C-index (0.9360; 95% CI, 0.9028-0.9769 vs. 0.9063; 95% CI, 0.8624-0.9628).
conclusionESGO 2025 and FIGO 2023 demonstrated distinct prognostic characteristics according to the clinical endpoint, suggesting complementary roles for molecularly integrated risk stratification and anatomical staging in the management of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.